Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Eur J Pharm Sci. 2021 Mar 27;162:105821. doi: 10.1016/j.ejps.2021.105821

Fig. 3.

Fig. 3.

Specificity of the DYRK1A harmine-related alkaloid inhibitors against a kinase panel. (A) To assess selectivity, compounds (at 10 μM) were profiled for selectivity against a panel of 10 kinases (Reaction Biology Corp., n = 2). Reductions in enzyme activity (%) are shown for each compound as a separate bar chart. (B) Human kinome map highlighting CMGC family with eight of the kinase selectivity panel highlighted by black circles and DYRK1A by a red circle. Human Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com).